BE891585A - 5 alpha-androstane-17 beta-carboxylates et 5 beta-androstane-17 beta-carboxylates, leur preparation et leur utilisation - Google Patents

5 alpha-androstane-17 beta-carboxylates et 5 beta-androstane-17 beta-carboxylates, leur preparation et leur utilisation

Info

Publication number
BE891585A
BE891585A BE0/206909A BE206909A BE891585A BE 891585 A BE891585 A BE 891585A BE 0/206909 A BE0/206909 A BE 0/206909A BE 206909 A BE206909 A BE 206909A BE 891585 A BE891585 A BE 891585A
Authority
BE
Belgium
Prior art keywords
beta
androstane
carboxylates
alpha
preparation
Prior art date
Application number
BE0/206909A
Other languages
English (en)
Inventor
D Ayer
C Schlagel
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of BE891585A publication Critical patent/BE891585A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C07J71/0015—Oxiranes at position 9(11)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0061—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16
    • C07J5/0069—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group
    • C07J5/0076—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group by an alkyl group
BE0/206909A 1980-12-22 1981-12-22 5 alpha-androstane-17 beta-carboxylates et 5 beta-androstane-17 beta-carboxylates, leur preparation et leur utilisation BE891585A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21929380A 1980-12-22 1980-12-22

Publications (1)

Publication Number Publication Date
BE891585A true BE891585A (fr) 1982-06-22

Family

ID=22818692

Family Applications (1)

Application Number Title Priority Date Filing Date
BE0/206909A BE891585A (fr) 1980-12-22 1981-12-22 5 alpha-androstane-17 beta-carboxylates et 5 beta-androstane-17 beta-carboxylates, leur preparation et leur utilisation

Country Status (8)

Country Link
JP (1) JPS57131000A (fr)
BE (1) BE891585A (fr)
DE (1) DE3149475A1 (fr)
FR (1) FR2496668A1 (fr)
GB (1) GB2089808A (fr)
IT (1) IT1142142B (fr)
NL (1) NL8105455A (fr)
ZA (1) ZA817929B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8501693D0 (sv) * 1985-04-04 1985-04-04 Draco Ab Novel 16,17-acetalsubstituted androstane-17beta-carboxylic acid esters
IL78144A0 (en) * 1985-04-04 1986-07-31 Draco Ab Novel androstane-17beta-carboxylic acid esters
WO1987002672A1 (fr) * 1985-10-23 1987-05-07 The Upjohn Company Steroides tetrahydro-angiostatiques
HUE027715T2 (en) 2008-05-28 2016-10-28 Reveragen Biopharma Inc NF-b non-hormonal steroid modulators for the treatment of disease
EP2556083A4 (fr) 2010-04-05 2013-12-04 Validus Biopharma Inc Modulateurs stéroïdes non hormonaux de nf- kappa b pour le traitement de maladies
WO2017004205A1 (fr) 2015-06-29 2017-01-05 Reveragen Biopharma, Inc. Modulateurs stéroïdiens non hormonaux de nf-κb pour le traitement de maladies
US11382922B2 (en) 2019-03-07 2022-07-12 Reveragen Biopharma, Inc. Aqueous oral pharmaceutical suspension compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3828080A (en) * 1972-01-20 1974-08-06 Glaxo Lab Ltd Androstane-17beta-carboxylic acids and processes for the preparation thereof
NL191792C (nl) * 1980-02-15 1996-08-02 Glaxo Group Ltd Esters van een androstaan-17beta-carbothiozuur, werkwijze ter bereiding van deze esters, en farmaceutische preparaten, die deze esters bevatten.

Also Published As

Publication number Publication date
IT1142142B (it) 1986-10-08
JPS57131000A (en) 1982-08-13
FR2496668A1 (fr) 1982-06-25
DE3149475A1 (de) 1982-07-15
GB2089808A (en) 1982-06-30
NL8105455A (nl) 1982-07-16
ZA817929B (en) 1982-10-27
IT8125692A0 (it) 1981-12-18

Similar Documents

Publication Publication Date Title
FR2504931B1 (fr) Ionomeres modifies, leur preparation et leur utilisation
BE884300A (fr) Amides, leur preparation et leur utilisation
BE879586A (fr) Phosphinylalcanoyl prolines, leur preparation et leur utilisation
LU81439A1 (fr) Octahydro-pyrazolo(3,4-g)quinoleines et leur utilisation therapeutique
MA19845A1 (fr) Nouvelles piperidinamines et leur preparation
BE890380A (fr) Pellicules thermoplastiques, leur preparation et leur utilisation
FR2573083B1 (fr) Copolymeres organosiloxane-oxyalkylene, leur preparation et leur utilisation
BE889401A (fr) 10-alcynyl steroides, leur preparation et leur utilisation
FI822164A0 (fi) Cylinderlaos-nyckelkombination, laoscylinder och nyckel foer denna kombination
BE896993A (fr) FACTEURS 1,2,3,4 et 5 DE TEICHOMYCINE A2, LEUR PREPARATION ET LEUR UTILISATION
BE882601A (fr) Mercaptoacyldipeptides, leur preparation et leur utilisation
FR2494689B1 (fr) Xanthates, leur preparation et leur utilisation
FR2511003B1 (fr) Alacaloides ergopeptidiques, leur preparation et leur utilisation comme medicaments
BE896018A (fr) Amides pyrrolacetiques, leur preparation et leur utilisation
OA07332A (fr) Oximes-éthers, leur préparation et leur utilisation.
BE855992A (fr) Inhibiteurs de testoterone 5 alpha-reductase, leur preparation et leur utilisation
BE871807A (fr) 4-quinolyl-guanidines, leur preparation et leur utilisation
BE889100A (fr) Derives de taurine, leur preparation et leur utilisation
BE887323A (fr) 17alpha-acyloxy-5 beta-corticoides et 17alpha-acyloxy-5alpha-corticoides, leur preparation et leur utilisation
BE885117A (fr) 3-amino-oxazolidin-2-ones, leur preparation et leur utilisation
BE882010A (fr) Tetrahydrobenzothiazolylimidazolidinones et leur utilisation
BE891585A (fr) 5 alpha-androstane-17 beta-carboxylates et 5 beta-androstane-17 beta-carboxylates, leur preparation et leur utilisation
BE880282A (fr) 4,1-benzoxazepines et 4,1-benzothiazepines
BE866728A (fr) 1,2,4-triazoles, leur preparation et leur utilisation
BE894056A (fr) 2-oxo-azetidines, leur preparation et leur utilisation

Legal Events

Date Code Title Description
RE Patent lapsed

Owner name: THE UPJOHN CY

Effective date: 19861231